The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT)

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 7, 2015, Pages 1301-1309

  Scorsetti, Marta ^a   Comito, Tiziana ^a   Cozzi, Luca ^a   Clerici, Elena ^a   Tozzi, Angelo ^a   Franzese, Ciro ^a   Navarria, Pierina ^a   Fogliata, Antonella ^b   Tomatis, Stefano ^a   D’Agostino, Giuseppo ^a   Iftode, Cristina ^a   Mancosu, Pietro ^a   Ceriani, Roberto ^a   Torzilli, Guido ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

Hepatocellular carcinoma; Liver; RapidArc; Stereotactic body radiation therapy

Indexed keywords

AGED; CARCINOMA, HEPATOCELLULAR; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; PATHOLOGY; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOSURGERY; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; DOSE FRACTIONATION; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RADIOSURGERY; RADIOTHERAPY DOSAGE; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 84938518091     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-015-1929-y     Document Type: Article

References (35)

1. Andolino DL, Johnson CS, Maluccio M et al (2011) Stereotactic body radio-therapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 81:e447–e453
2. Bibault JE, Dewas S, Vautravers-Dewas C et al (2013) Stereotactic body radiation therapy for hepatocellular carcinoma: prognostic factors of local control, overall survival, and toxicity. PLoS One 8:e77472
3. Bujold A, Massey CA, Kim JJ et al (2012) Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol 44:1659
4. Cardenes HR, Price TR, Perkins SM et al (2010) Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma. Clin Transl Oncol 12:218–225
5. Cheng AL, Kang YK, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34
6. Choi BO, Choi IB, Jang HS et al (2008) Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer 8:351
7. Culleton S, Jiang H, Haddad CR et al (2014) Outcomes following definitive stereotactic body radiotherapy for patients with Child–Turcotte–Pugh B or C hepatocellular carcinoma. Radiother Oncol 111:412–417
8. Dawson LA, Normolle D, Balter JM, McGinn C, Lawrence T, Ten Haken R (2002) Analysis of radiation induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 53:810–821
9. Dewas S, Bibault JE, Mirabel X et al (2012) Prognostic factors affecting local control of hepatic tumors treated by stereotactic body radiation therapy. Radiat Oncol 7:166
10. Eisenhauer E, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
11. Eriguchi T, Takeda A, Sanuki N et al (2013) Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system. Int J Radiat Oncol Biol Phys 85:1006–1011
12. European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer (2012) EASL–EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56:908–943
13. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917
14. Goodman KA, Wiegner EA, Maturen KE et al (2010) Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys 78:486–493
15. Herfarth KK, Debus J, Lohr F et al (2001) Stereotactic single-dose radiation therapy of liver tumors: results of a phase I/II trial. J Clin Oncol 19:164–170
16. Huang WY, Jen YM, Lee MS et al (2012) Stereotactic body radiation therapy in recurrent hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 84:355–361
17. Jacob R, Turley F, Redden D et al (2014) Adjuvant stereotactic body radiotherapy following transarterial chemoembolization in patients with non-resectable hepatocellular carcinoma tumours of ≥3 cm. HPB, Oxford
18. Kang JK, Kim MS, Cho CK et al (2012) Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer 118:5424–5431
19. Klein J, Dawson LA (2013) Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys 87:22–32
20. Kwon JH, Bae SH, Kim JY et al (2010) Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer. BMC Cancer 10:475
21. Lawrence TS, Robertson JM, Anscher MS, Jirtle R, Ensminger W, Fajardo L (1995) Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 31:1237–1248
22. Llovet JM, Fuster J, Bruix J (1999) Intention-to treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30:1434–1440
23. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390
24. Llower JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442
25. Mendez Romero A, Wunderink W, Hussain SM et al (2006) Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase I–II study. Acta Oncol 45:831–837
26. Oliveri RS, Wetterslev J, Gluud C (2011) Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 3:CD004787
27. Park JH, Yoon SM, Lim YS et al (2013) Two-week schedule of hypofractionated radiotherapy as a local salvage treatment for small hepatocellular carcinoma. J Gastroenterol Hepatol 28:1638–1642
28. Que JY, Lin LC, Lin KL, Lin CH, Lin YW, Yang CC (2014) The efficacy of stereotactic body radiation therapy on huge hepatocellular carcinoma unsuitable for other local modalities. Radiat Oncol 9:120
29. Sanuki N, Takeda A, Oku Y et al (2014a) Stereotactic body radiotherapy for small hepatocellular carcinoma: a retrospective outcome analysis in 185 patients. Acta Oncol 53:399–404
30. Sanuki N, Takeda A, Kunieda E et al (2014b) Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J Gastroenterol 20:3100–3111
31. Scorsetti M, Arcangeli S, Tozzi A, Comito T, Alongi F, Navarria P (2013) Is stereotactic body radiation therapy an attractive option for unresectable liver metastases? A preliminary report from a phase 2 trial. Int J Radiat Oncol Biol Phys 86:336–342
32. Seo YS, Kim MS, Yoo SY et al (2010) Preliminary result of stereotactic body radiotherapy as a local salvage treatment for inoperable hepatocellular carcinoma. J Surg Oncol 102:209–214
33. Tse RV, Hawkins M, Lockwood G et al (2008) Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol 26:657–664
34. Xi M, Zhang L, Zhao L et al (2013) Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLoS One 8:e63864
35. Zhong NB, Lv GM, Chen ZH (2014) Stereotactic body radiotherapy combined with transarterial chemoembolization for huge (≥10 cm) hepatocellular carcinomas: a clinical study. Mol Clin Oncol 2:839–844